Tegoprazan Hydrochloride Tablets are China’s first Class I innovative P-CAB drug with independent intellectual property rights, developed by Jiangsu Carephar Pharmaceutical Co., Ltd. and manufactured by Nanjing Carephar Shenghui Pharmaceutical Co., Ltd. This innovative drug has broken the foreign monopoly and been granted 9 patents in China, the U.S., Europe and Japan, and is also the world’s first P-CAB medicine approved for Hp eradication indication. With fast, strong, long‑lasting and stable acid inhibition, it achieves an Hp eradication rate of 93.5%, and is highly effective in treating reflux esophagitis and duodenal ulcer while greatly improving the primary prevention of gastric cancer, offering a world‑class domestic solution for gastrointestinal diseases with its clinical value widely recognized by authoritative experts at home and abroad.